Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down – What’s Next?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $25.00, but opened at $23.85. Centessa Pharmaceuticals shares last traded at $23.7450, with a volume of 3,031 shares.

Wall Street Analyst Weigh In

Several research firms recently commented on CNTA. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Oppenheimer lifted their price target on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Guggenheim raised their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, Stephens assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $38.50.

Centessa Pharmaceuticals Trading Down 0.2%

The stock has a market cap of $3.16 billion, a PE ratio of -12.84 and a beta of 1.56. The stock has a 50-day moving average price of $25.22 and a two-hundred day moving average price of $22.62. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Sell-side analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This trade represents a 5.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 89,961 shares of company stock worth $2,344,878. 7.09% of the stock is owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Centessa Pharmaceuticals during the 2nd quarter valued at about $218,000. DNB Asset Management AS purchased a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth approximately $218,000. Finally, Sigma Planning Corp acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $225,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.